Genetic Variants within Endothelial Nitric Oxide Synthase Gene and Prostate Cancer: A Meta‐Analysis
Several variants within gene‐encoding endothelial isoform of nitric oxide synthase have been reported to confer prostate cancer (PCa) susceptibility and/or progression. Nevertheless, studies referring to this issue have yielded inconsistent results. In order to elucidate the involvement of these var...
Gespeichert in:
| Veröffentlicht in: | Clinical and translational science 2015-02, Vol.8 (1), p.23-31 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 31 |
|---|---|
| container_issue | 1 |
| container_start_page | 23 |
| container_title | Clinical and translational science |
| container_volume | 8 |
| creator | Nikolić, Zorana Z. Pavićević, Dušanka Lj. Savić Romac, Stanka P. Brajušković, Goran N. |
| description | Several variants within gene‐encoding endothelial isoform of nitric oxide synthase have been reported to confer prostate cancer (PCa) susceptibility and/or progression. Nevertheless, studies referring to this issue have yielded inconsistent results. In order to elucidate the involvement of these variants in prostate carcinogenesis, we have conducted a meta‐analysis of previously published case‐control and relevant case‐only studies. Eleven studies comprising in total 3,806 cases and 4,466 controls were included in the meta‐analysis which yielded evidence of association of rs2070744 (ORCC = 1.43, 95% CI 1.04–1.97; p = 0.03) and intron 4a/b variant (ORab+aa = 1.47, 95% CI 1.00–2.14; p = 0.05) with PCa risk under recessive and dominant model, respectively. Furthermore, PCa patients carrying 4a/b a allele were found to have an increased risk of cancer progression to a less differentiated form, characterized by a high Gleason score (OR = 2.29, 95% CI 1.51–3.49; p < 0.01) and to higher TNM stage (OR = 2.55, 95% CI 1.71–3.81; p < 0.01). These results support the involvement of NOS3 variants in molecular pathogenesis of PCa. |
| doi_str_mv | 10.1111/cts.12203 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_24P</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5350916</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1668258146</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5123-28f80228851056eaf4c8e491adfd5babdf27f8b5fc59a8209062a9ad6a303f843</originalsourceid><addsrcrecordid>eNpdkclKBDEQhoMo7gdfQAJevIwm6U4m7UEYBjdwA5drqOmudiI9aU0y6tx8BJ_RJzHjMqh1qYL66ucvfkI2ONvhqXbLGHa4ECybI8u8K0VHMyXmZ7PMl8hKCPeMqUxpuUiWhOQqF121TPAIHUZb0lvwFlwM9NnGoXX0wFVtHGJjoaHnNvqEXLzYCunVxMUhBKTTSwquope-DREi0j64Ev0e7dEzjPD--tZz0EyCDWtkoYYm4Pp3XyU3hwfX_ePO6cXRSb932iklF1lH6FozIbSWnEmFUOelxrzgUNWVHMCgqkW31gNZl7IALViR3oQCKgUZy2qdZ6tk_0v3YTwYYVWiix4a8-DtCPzEtGDN342zQ3PXPhmZSVZwlQS2vwV8-zjGEM3IhhKbBhy242C4UlpIzfMpuvUPvW_HPj08pWSueQJFojZ_O5pZ-UkgAbtfwLNtcDLbc2am0ZoUrfmM1vSvrz6H7ANcdZdI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1654818252</pqid></control><display><type>article</type><title>Genetic Variants within Endothelial Nitric Oxide Synthase Gene and Prostate Cancer: A Meta‐Analysis</title><source>Wiley-Blackwell Open Access Titles</source><creator>Nikolić, Zorana Z. ; Pavićević, Dušanka Lj. Savić ; Romac, Stanka P. ; Brajušković, Goran N.</creator><creatorcontrib>Nikolić, Zorana Z. ; Pavićević, Dušanka Lj. Savić ; Romac, Stanka P. ; Brajušković, Goran N.</creatorcontrib><description>Several variants within gene‐encoding endothelial isoform of nitric oxide synthase have been reported to confer prostate cancer (PCa) susceptibility and/or progression. Nevertheless, studies referring to this issue have yielded inconsistent results. In order to elucidate the involvement of these variants in prostate carcinogenesis, we have conducted a meta‐analysis of previously published case‐control and relevant case‐only studies. Eleven studies comprising in total 3,806 cases and 4,466 controls were included in the meta‐analysis which yielded evidence of association of rs2070744 (ORCC = 1.43, 95% CI 1.04–1.97; p = 0.03) and intron 4a/b variant (ORab+aa = 1.47, 95% CI 1.00–2.14; p = 0.05) with PCa risk under recessive and dominant model, respectively. Furthermore, PCa patients carrying 4a/b a allele were found to have an increased risk of cancer progression to a less differentiated form, characterized by a high Gleason score (OR = 2.29, 95% CI 1.51–3.49; p < 0.01) and to higher TNM stage (OR = 2.55, 95% CI 1.71–3.81; p < 0.01). These results support the involvement of NOS3 variants in molecular pathogenesis of PCa.</description><identifier>ISSN: 1752-8054</identifier><identifier>EISSN: 1752-8062</identifier><identifier>DOI: 10.1111/cts.12203</identifier><identifier>PMID: 25164276</identifier><language>eng</language><publisher>United States: John Wiley & Sons, Inc</publisher><subject>4a/b ; Alleles ; Genetic Predisposition to Disease ; Humans ; Introns - genetics ; Male ; meta‐analysis ; Nitric oxide ; Nitric Oxide Synthase Type III - genetics ; NOS3 ; Original s ; Polymorphism, Single Nucleotide - genetics ; Prostate cancer ; Prostatic Neoplasms - enzymology ; Prostatic Neoplasms - genetics ; Risk Factors ; rs1799983 ; rs2070744</subject><ispartof>Clinical and translational science, 2015-02, Vol.8 (1), p.23-31</ispartof><rights>2014 Wiley Periodicals, Inc.</rights><rights>2015 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5123-28f80228851056eaf4c8e491adfd5babdf27f8b5fc59a8209062a9ad6a303f843</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5350916/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5350916/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,1417,11562,27924,27925,45574,45575,46052,46476,53791,53793</link.rule.ids><linktorsrc>$$Uhttps://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcts.12203$$EView_record_in_Wiley-Blackwell$$FView_record_in_$$GWiley-Blackwell</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25164276$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nikolić, Zorana Z.</creatorcontrib><creatorcontrib>Pavićević, Dušanka Lj. Savić</creatorcontrib><creatorcontrib>Romac, Stanka P.</creatorcontrib><creatorcontrib>Brajušković, Goran N.</creatorcontrib><title>Genetic Variants within Endothelial Nitric Oxide Synthase Gene and Prostate Cancer: A Meta‐Analysis</title><title>Clinical and translational science</title><addtitle>Clin Transl Sci</addtitle><description>Several variants within gene‐encoding endothelial isoform of nitric oxide synthase have been reported to confer prostate cancer (PCa) susceptibility and/or progression. Nevertheless, studies referring to this issue have yielded inconsistent results. In order to elucidate the involvement of these variants in prostate carcinogenesis, we have conducted a meta‐analysis of previously published case‐control and relevant case‐only studies. Eleven studies comprising in total 3,806 cases and 4,466 controls were included in the meta‐analysis which yielded evidence of association of rs2070744 (ORCC = 1.43, 95% CI 1.04–1.97; p = 0.03) and intron 4a/b variant (ORab+aa = 1.47, 95% CI 1.00–2.14; p = 0.05) with PCa risk under recessive and dominant model, respectively. Furthermore, PCa patients carrying 4a/b a allele were found to have an increased risk of cancer progression to a less differentiated form, characterized by a high Gleason score (OR = 2.29, 95% CI 1.51–3.49; p < 0.01) and to higher TNM stage (OR = 2.55, 95% CI 1.71–3.81; p < 0.01). These results support the involvement of NOS3 variants in molecular pathogenesis of PCa.</description><subject>4a/b</subject><subject>Alleles</subject><subject>Genetic Predisposition to Disease</subject><subject>Humans</subject><subject>Introns - genetics</subject><subject>Male</subject><subject>meta‐analysis</subject><subject>Nitric oxide</subject><subject>Nitric Oxide Synthase Type III - genetics</subject><subject>NOS3</subject><subject>Original s</subject><subject>Polymorphism, Single Nucleotide - genetics</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms - enzymology</subject><subject>Prostatic Neoplasms - genetics</subject><subject>Risk Factors</subject><subject>rs1799983</subject><subject>rs2070744</subject><issn>1752-8054</issn><issn>1752-8062</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkclKBDEQhoMo7gdfQAJevIwm6U4m7UEYBjdwA5drqOmudiI9aU0y6tx8BJ_RJzHjMqh1qYL66ucvfkI2ONvhqXbLGHa4ECybI8u8K0VHMyXmZ7PMl8hKCPeMqUxpuUiWhOQqF121TPAIHUZb0lvwFlwM9NnGoXX0wFVtHGJjoaHnNvqEXLzYCunVxMUhBKTTSwquope-DREi0j64Ev0e7dEzjPD--tZz0EyCDWtkoYYm4Pp3XyU3hwfX_ePO6cXRSb932iklF1lH6FozIbSWnEmFUOelxrzgUNWVHMCgqkW31gNZl7IALViR3oQCKgUZy2qdZ6tk_0v3YTwYYVWiix4a8-DtCPzEtGDN342zQ3PXPhmZSVZwlQS2vwV8-zjGEM3IhhKbBhy242C4UlpIzfMpuvUPvW_HPj08pWSueQJFojZ_O5pZ-UkgAbtfwLNtcDLbc2am0ZoUrfmM1vSvrz6H7ANcdZdI</recordid><startdate>201502</startdate><enddate>201502</enddate><creator>Nikolić, Zorana Z.</creator><creator>Pavićević, Dušanka Lj. Savić</creator><creator>Romac, Stanka P.</creator><creator>Brajušković, Goran N.</creator><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7QP</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>5PM</scope></search><sort><creationdate>201502</creationdate><title>Genetic Variants within Endothelial Nitric Oxide Synthase Gene and Prostate Cancer: A Meta‐Analysis</title><author>Nikolić, Zorana Z. ; Pavićević, Dušanka Lj. Savić ; Romac, Stanka P. ; Brajušković, Goran N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5123-28f80228851056eaf4c8e491adfd5babdf27f8b5fc59a8209062a9ad6a303f843</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>4a/b</topic><topic>Alleles</topic><topic>Genetic Predisposition to Disease</topic><topic>Humans</topic><topic>Introns - genetics</topic><topic>Male</topic><topic>meta‐analysis</topic><topic>Nitric oxide</topic><topic>Nitric Oxide Synthase Type III - genetics</topic><topic>NOS3</topic><topic>Original s</topic><topic>Polymorphism, Single Nucleotide - genetics</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms - enzymology</topic><topic>Prostatic Neoplasms - genetics</topic><topic>Risk Factors</topic><topic>rs1799983</topic><topic>rs2070744</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nikolić, Zorana Z.</creatorcontrib><creatorcontrib>Pavićević, Dušanka Lj. Savić</creatorcontrib><creatorcontrib>Romac, Stanka P.</creatorcontrib><creatorcontrib>Brajušković, Goran N.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical and translational science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Nikolić, Zorana Z.</au><au>Pavićević, Dušanka Lj. Savić</au><au>Romac, Stanka P.</au><au>Brajušković, Goran N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Genetic Variants within Endothelial Nitric Oxide Synthase Gene and Prostate Cancer: A Meta‐Analysis</atitle><jtitle>Clinical and translational science</jtitle><addtitle>Clin Transl Sci</addtitle><date>2015-02</date><risdate>2015</risdate><volume>8</volume><issue>1</issue><spage>23</spage><epage>31</epage><pages>23-31</pages><issn>1752-8054</issn><eissn>1752-8062</eissn><abstract>Several variants within gene‐encoding endothelial isoform of nitric oxide synthase have been reported to confer prostate cancer (PCa) susceptibility and/or progression. Nevertheless, studies referring to this issue have yielded inconsistent results. In order to elucidate the involvement of these variants in prostate carcinogenesis, we have conducted a meta‐analysis of previously published case‐control and relevant case‐only studies. Eleven studies comprising in total 3,806 cases and 4,466 controls were included in the meta‐analysis which yielded evidence of association of rs2070744 (ORCC = 1.43, 95% CI 1.04–1.97; p = 0.03) and intron 4a/b variant (ORab+aa = 1.47, 95% CI 1.00–2.14; p = 0.05) with PCa risk under recessive and dominant model, respectively. Furthermore, PCa patients carrying 4a/b a allele were found to have an increased risk of cancer progression to a less differentiated form, characterized by a high Gleason score (OR = 2.29, 95% CI 1.51–3.49; p < 0.01) and to higher TNM stage (OR = 2.55, 95% CI 1.71–3.81; p < 0.01). These results support the involvement of NOS3 variants in molecular pathogenesis of PCa.</abstract><cop>United States</cop><pub>John Wiley & Sons, Inc</pub><pmid>25164276</pmid><doi>10.1111/cts.12203</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | ISSN: 1752-8054 |
| ispartof | Clinical and translational science, 2015-02, Vol.8 (1), p.23-31 |
| issn | 1752-8054 1752-8062 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5350916 |
| source | Wiley-Blackwell Open Access Titles |
| subjects | 4a/b Alleles Genetic Predisposition to Disease Humans Introns - genetics Male meta‐analysis Nitric oxide Nitric Oxide Synthase Type III - genetics NOS3 Original s Polymorphism, Single Nucleotide - genetics Prostate cancer Prostatic Neoplasms - enzymology Prostatic Neoplasms - genetics Risk Factors rs1799983 rs2070744 |
| title | Genetic Variants within Endothelial Nitric Oxide Synthase Gene and Prostate Cancer: A Meta‐Analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T11%3A23%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_24P&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Genetic%20Variants%20within%20Endothelial%20Nitric%20Oxide%20Synthase%20Gene%20and%20Prostate%20Cancer:%20A%20Meta%E2%80%90Analysis&rft.jtitle=Clinical%20and%20translational%20science&rft.au=Nikoli%C4%87,%20Zorana%20Z.&rft.date=2015-02&rft.volume=8&rft.issue=1&rft.spage=23&rft.epage=31&rft.pages=23-31&rft.issn=1752-8054&rft.eissn=1752-8062&rft_id=info:doi/10.1111/cts.12203&rft_dat=%3Cproquest_24P%3E1668258146%3C/proquest_24P%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1654818252&rft_id=info:pmid/25164276&rfr_iscdi=true |